MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/po-25-00310

Медицинская библиотека · JCO precision oncology · 2025

Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Aldea Mihaela, Orillard Emeline, Bernard-Tessier Alice, Cerbone Luigi, Llacer Casilda, Koster Kira-Lee, Roubaud Guilhem, De Giorgi Ugo, Joly Florence, Cherifi François, Rochand Adrien, Omlin Aurelius, Beltran Himisha, Morales-Barrera Rafael, Annonay Mylene, Bianchini Diletta, de Bono Johann, Castro Elena, Baciarello Giulia, Gillessen Silke, Thiery-Vuillemin Antoine, Fizazi Karim

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in BRCA2. PARP inhibitors (PARPi) are standard treatments for BRCA1/2-altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations.

METHODS

This multicenter, retrospective study included patients with mCRPC with known DDR status treated with platinum monotherapy. DDR-positive (DDR+) patients had deleterious germline or somatic alterations in DDR genes (BRCA1, BRCA2, CDK12, ATM, CHEK2, PALB2, or FANCA), whereas DDR-negative (DDR-) patients had no such alterations. Prostate-specific antigen (PSA) response, progression-free survival (PFS, PSA/clinical/radiographic), and overall survival (OS) were assessed in DDR+ and DDR- groups.

RESULTS

Among 129 patients, 81 had DDR+ and 48 had DDR- cancers. A PSA decline of ≥50% was demonstrated in 48% in BRCA, 9% in DDR+ non-BRCA, and 13% in DDR- patients (P < .0001). Objective responses occurred in 37.5% in BRCA, 11% in DDR+ non-BRCA, and 13% in DDR- patients (P = .017). No response was reported in DDR+ patients who had received previous PARPi (n = 16). The median PSA response was 5 months for BRCA, 2 months for DDR+ non-BRCA, and 1.7 months for DDR- patients, respectively (P = .015), whereas the median clinical/radiographic PFS was 4.7 months, 2.8 months, and 2 months, respectively (P = .2). In PARPi-naïve patients, the median OS was 13.7 months for BRCA, 8.7 months for DDR+ non-BRCA, and 6.1 months for DDR- patients (P = .013).

CONCLUSION

Single-agent platinum agents show significant anticancer activity in BRCA-mutated patients with mCRPC without previous PARPi exposure. With their low cost and broad availability, platinum agents offer a practical alternative, particularly in regions where PARPi are inaccessible.

Для цитирования: Aldea Mihaela, Orillard Emeline, Bernard-Tessier Alice, Cerbone Luigi, Llacer Casilda, Koster Kira-Lee, Roubaud Guilhem, De Giorgi Ugo, Joly Florence, Cherifi François, Rochand Adrien, Omlin Aurelius, Beltran Himisha, Morales-Barrera Rafael, Annonay Mylene, Bianchini Diletta, de Bono Johann, Castro Elena, Baciarello Giulia, Gillessen Silke, Thiery-Vuillemin Antoine, Fizazi Karim. Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.. JCO precision oncology. 2025. DOI: 10.1200/po-25-00310.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.